Results 11 to 20 of about 253,625 (250)

The Tight Relationship Between the Tumoral Microenvironment and Radium-223 [PDF]

Biomedicines
Radium-223 (223Ra) was the first radioactive isotope approved for treating castration-resistant prostate cancer (CRPC) with symptomatic bone metastases without visceral metastatic disease.
Miriam Conte, Miriam Tomaciello, Maria Silvia De Feo, Viviana Frantellizzi, Francesco Marampon, Flaminia De Cristofaro, Giuseppe De Vincentis, Luca Filippi   +7 more
doaj   +3 more sources

Bilateral neovascular glaucoma associated with Radium-223 infusions for prostate cancer [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report two cases of neovascular glaucoma associated with Radium-223 infusion. Observations: Presented are two patients with metastatic prostate cancer who developed uncontrolled intraocular pressure secondary to neovascular glaucoma requiring
Chelsea M. Viscardi, Jonathan Y. Rho, Charles R. Blake   +2 more
doaj   +3 more sources

Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies [PDF]

Diagnostics
Recent advances have broadened the range of therapeutic options for mCRPC, with several new treatments, including novel hormonal therapies (enzalutamide, abiraterone), chemotherapeutic agents (docetaxel, cabazitaxel), immunotherapies (sipuleucel-T), and ...
Ali H. D. Alshehri
doaj   +3 more sources

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

New England Journal of Medicine, 2013
Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration ...
S I Helle, J Logue, Peter Hoskin
exaly   +3 more sources

Radium 223 dichloride for prostate cancer treatment

Drug Design, Development and Therapy, 2017
Emmanuel Deshayes,1,2 Mathieu Roumiguie,3 Constance Thibault,4 Philippe Beuzeboc,5 Florent Cachin,6 Christophe Hennequin,7 Damien Huglo,8 François Rozet,9 Diana Kassab-Chahmi,10 Xavier Rebillard,11 Nadine Houédé1,12 1Radiobiology ...
Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houédé N   +10 more
doaj   +8 more sources

Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients. [PDF]

Eur J Nucl Med Mol Imaging
Radium- 223 and Lutetium- 177 prostate-specific membrane antigen radioligand therapy (Lu- 177-PSMA) are approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Wenzel M, Theissen L, Groener D, Kriegmair M, Graefen M, Maurer T, Salomon G, Hoeh B, Siech C, Banek S, Chun FKH, Mandel P.   +11 more
europepmc   +2 more sources

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context

EClinicalMedicine, 2023
Summary: Background: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in ...
Celestia S. Higano, Daniel J. George, Neal D. Shore, Oliver Sartor, Kurt Miller, Peter S. Conti, Cora N. Sternberg, Fred Saad, Juan Pablo Sade, Joaquim Bellmunt, Matthew R. Smith, Kumari Chandrawansa, Per Sandström, Frank Verholen, Bertrand Tombal   +14 more
doaj   +2 more sources

Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study [PDF]

Acta Oncologica
Background: The role and optimal sequencing of radium-223 in the treatment of metastatic castration-resistant prostate cancer (mCRPC) remain debated.
Charlotte Alverbratt, Fredrik Sandin, Viktor Kolmbäck, Hans Garmo, Ola Bratt, Ingela Franck Lissbrant   +5 more
doaj   +2 more sources

Investigation of the safety of Radium-223 chloride in combination with external beam radiotherapy for bone metastases of prostate cancer. [PDF]

J Radiat Res
This study aimed to investigate the safety of combining radium-223 chloride (Ra-223) therapy with external beam radiation therapy (EBRT) for patients with multiple bone metastases from castration-resistant prostate cancer (CRPC), including lesions ...
Makino S, Miyazawa K, Katsuoka Y, Ooe T, Aikawa K, Segawa A, Kobayashi H.   +6 more
europepmc   +2 more sources

Exhalation of Rn-219 by patients treated with Radium-223. [PDF]

EJNMMI Phys
Treatment with Ra-223 dichloride is approved for the therapy of castration resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastases in Europe since 2013, and Ra-223 is under discussion for labelling other ...
Wanke C, Pinkert J, Geworski L, Szermerski B.   +3 more
europepmc   +2 more sources